Update: PBAC OutcomeThe PBAC recommended that both Kadcyla and Perjeta be added to the PBS. The Australian Government accepted the recommendation and both drugs were listed from 1 July 2015.
BCNA has made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of two new drugs used to treat HER2-positive secondary breast cancer. The PBAC is the authority that makes recommendations to the Australian Government on which drugs should be subsidised through the Pharmaceutical Benefits Schedule (PBS).
It is the third time that Kadcyla (T-DM1) and the second time that Perjeta (pertuzumab) have been considered by PBAC.
Kadcyla and Perjeta have both been shown in clinical trials to extend life for women living with secondary breast cancer.